


Figure S1. Changes in uPA and uPAR expression in (A) HPV-positive and (B) HPV-negative groups after EBRT. HPV, human papillomavirus; uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen activator receptor; EBRT, external beam radiation therapy.

A



B




Figure S2. Association of disease-free survival of patients associated with pretreatment levels of (A) uPA and (B) uPAR, uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen activator receptor.




Figure S3. Association of disease-free survival of patients who completed external beam radiation therapy with the levels of (A) uPA and (B) uPAR, uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen activator receptor.




Figure S4. Association of overall survival of the patients with pretreatment levels of (A) uPA and (B) uPAR, uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen activator receptor.




Figure S5. Association of overall survival of the patients who completed external beam radiation therapy with the levels of (A) uPA and (B) uPAR, uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen activator receptor.

